Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Study Identifier:
ECU-MG-301
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Eculizumab
- Drug: Placebo
Date
Dec 2013 - Feb 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Eculizumab
- Drug: Placebo
Date
Dec 2013 - Feb 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.
Trial Locations
Location
Status
Location
University of Alabama
Birmingham, Alabama, United States, 35233
Status
N/A
Location
University of California San Francisco-Fresno
Fresno, California, United States, 93720
Status
N/A
Location
University of Southern California
Los Angeles, California, United States, 90033
Status
N/A
Location
University of California-Irvine
Orange, California, United States, 92868
Status
N/A
Location
University of California Davis Health System
Sacramento, California, United States, 95765
Status
N/A
Location
California Pacific Medical Center
San Francisco, California, United States, 94115
Status
N/A